A carregar...
The evolving world of GLP-1 agonist therapies for type 2 diabetes
The glucagon-like peptide-1 (GLP-1) agonist drugs have attractions as a treatment for type 2 diabetes since they positively alter a number of key pathophysiological defects. These include increasing insulin release, reducing glucagon release, slowing gastric emptying and reducing food intake. In num...
Na minha lista:
| Autor principal: | |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
SAGE Publications
2010
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3475287/ https://ncbi.nlm.nih.gov/pubmed/23148151 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2042018810375414 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|